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The immunogenicity of capsomeres of human papillomavirus type 33 was evaluated in a dose–response analysis.
Capsomeres were obtained free of capsids by expression of L1 carrying the single point mutation C427S. Neutralizing
antibodies were detected using an in vitro pseudoinfection assay. Capsomeres induced type-specific, neutralizing antibodies
in mice even in the absence of adjuvant. The neutralization titers of immune sera raised without adjuvant were 10- to 20-fold
lower than those of antisera to virus-like particles, but virtually identical using Freund’s adjuvant. These data indicate that
capsomeres may substitute for virus-like particles in future vaccines when used with an adjuvant appropriate for human
vaccination. © 2001 Academic Press
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Human papillomaviruses (HPV) are nonenveloped,
double-stranded DNA viruses of higher vertebrates in-
fecting keratinocytes of the skin and mucosa in a highly
species- and tissue-specific manner. Infection usually
results in benign epithelial hyperproliferations but in
some instances such lesions may undergo malignant
transformation. Many tumors of the anogenital and oral
mucosa and some tumors of the skin are strongly asso-
ciated with a few specific types of human papillomavirus
(zur Hausen and de Villiers, 1994). A prominent example
is invasive cervical carcinoma, which in 90–95% of all
cases was found to be associated with human papillo-
mavirus infection, mainly of type 16, 18, 31, 33, 35, or 45
(Bosch et al., 1995). The only cure today is the surgical
removal of the lesions. This has prompted many efforts
aiming at the development of a vaccine for the preven-
tion of HPV infections.
The icosahedral capsid of papillomaviruses consists
of 72 capsomeres arranged on a T 5 7 icosahedral
surface lattice (Baker et al., 1991). Capsomeres are pen-
tamers of the major capsid protein L1 and are nonco-
valently associated. L1 molecules of adjacent capso-
meres are linked by disulfide bonds between two highly
conserved cysteines, which in HPV-33 are C176 and
C427 (Sapp et al., 1998), to form trimers. Mutation of
either C176 or C427 completely prevents the assembly of
1 To whom correspondence and reprint requests should be ad-
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utenberg-Universita¨t Mainz, Hochhaus am Augustusplatz, D-55101
ainz, Germany. Fax: 149-6131-393-2359. E-mail: sapp@mail.uni-
ainz.de.353capsids but not of capsomeres. The capsid harbors
some copies of the minor capsid protein L2, in addition
to L1, which are noncovalently associated with capso-
meres (Sapp et al., 1995).
Only few HPV types can be propagated outside the
natural host, and the yields of virions are usually very
low, which makes it impossible to test attenuated viruses
as vaccine candidates. Recently several groups have
generated virus-like particles (VLPs) by synthesizing the
major capsid protein L1 either alone or together with the
minor capsid protein L2 using heterologous expression
systems, e.g., recombinant baculoviruses (Kirnbauer et
al., 1992; Rose et al., 1993; Volpers et al., 1994), vaccinia
viruses (Zhou et al., 1991; Hagensee et al., 1993), or yeast
(Hofmann et al., 1995; Sasawaga et al., 1995). VLPs are
not infectious because of the lack of a viral genome but
are structurally indistinguishable from virions as deter-
mined by cryoelectron microscopy and three-dimen-
sional image reconstruction at 3.5-nm resolution (Ha-
gensee et al., 1994). Using animal models and in vitro
infectivity assays, it was shown that antibodies to VLPs
exhibit strong neutralizing potential (Breitburd et al.,
1995; Christensen et al., 1994; Roden et al., 1996; Rose et
al., 1994; Suzich et al., 1995; Unckell et al., 1997). In
contrast to VLPs, capsomeres can be efficiently gener-
ated in bacteria and were therefore also considered as
candidate vaccine. Rose et al. (1998) recently reported
that capsomeres of the low-risk HPV-11 generated by
trypsin digestion of L1 at R415 carry antigenic determi-
nants sufficient for mounting a virus-neutralizing immune
response. However, Freund’s adjuvant was used in this
study, which would not be applicable in human vaccines,
and the relative efficacy of capsomeres vs that of VLPs0042-6822/01 $35.00
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354 FLIGGE ET AL.was not determined. In addition, the L1 protein forming
the capsomeres lacked the 86 C-terminal amino acids.
We have now generated capsomeres of high-risk HPV-33
L1 differing from the wild-type protein by a single point
mutation, C427S, and have used these capsomeres for a
dose–response comparison with VLPs, both in the pres-
ence and in the absence of adjuvant. The titers of neu-
tralizing antibody induced in mice were determined us-
ing an in vitro system (Unckell et al., 1997) which closely
imics a natural infection (Giroglou et al., 2001a). This is
he first dose–response analysis of capsomeres of one
f the high-risk viruses, which are actually the main
arget in prophylactic vaccine development.
RESULTS AND DISCUSSION
We have previously shown that mutation of either of
he cysteines C427 or C176 of HPV-33 L1 prevents the
ormation of essential disulfide bonds by which adjacent
apsomeres of the HPV capsid are tied together (Sapp et
l., 1998). Capsomeres made of HPV-33 L1 carrying a
427S mutation are therefore unable to assemble into
LPs, in contrast to capsomeres generated from wild-
ype protein (Fig. 1A). The genetically modified L1 protein
hus offers the possibility of generating capsomeres in
ure form, free of contaminating capsids.
We have used this approach for the production of
apsomeres of HPV-33 and have compared the immuno-
enicity of capsomeres and VLPs. In an initial experi-
ent mice were immunized with a high dose of purified
apsomeres or VLPs. The amount of L1 protein injected
approximately 7 mg each) was quantified by Western
lotting (Fig. 1B). In this initial experiment capsomeres
nd VLPs used for the primary and booster injection
ere emulsified in complete and incomplete Freund’s
djuvant, respectively. The immunogenicity of capso-
eres and VLPs was then evaluated by VLP ELISA.
sing this immunization protocol, the endpoint titers of
he antisera obtained were virtually identical (data not
hown). Neutralizing antibodies were titrated using an in
itro infectivity assay, i.e., infection of COS-7 cells by
seudovirions encapsidating plasmids encoding green
luorescent protein (GFP) or b-galactosidase (Unckell et
al., 1997). This assay exhibits features characteristic of a
natural infection, e.g., the type specificity of neutraliza-
tion (Giroglou et al., 2001b), the importance of the minor
capsid protein L2 (Unckell et al., 1997), the use of hepa-
ran sulfate as primary receptor, and the postattachment
neutralization (Giroglou et al., 2001a). As shown in Fig.
1C, the titer of neutralizing antibodies raised by capso-
meres and VLPs, respectively, as determined by this
assay, was again similar, approximately 1:104 at 50%
neutralization. These data suggested that most of the
neutralization epitopes were entirely contained within
capsomeres and prompted a more detailed dose–re-
sponse analysis. Three mice each were immunized with0.5, 1.5, 4.5, 7, and 14 mg of VLPs or capsomeres dis-
solved in Freund’s adjuvant. Blood was taken 2 weeks
after the first and second boost, respectively, which was
administered in incomplete Freund’s adjuvant. For all
analyses, sera of the three mice, immunized with the
same dose of antigen, were pooled and tested in at least
three independent assays. ELISA data showed that 0.5
mg antigen was sufficient to induce a very good immune
response, yielding endpoint titers of about 3 3 106 (Table
1). A significant increase in the amount of antigen ad-
ministered did not substantially improve the immune
response as measured by ELISA (Table 1). Surprisingly,
again no significant difference was observed between
the immunogenicity of capsomeres and that of VLPs.
When tested for the presence of neutralizing antibod-
ies, the VLP and capsomere antisera were once more
found to have similar titers (Figs. 2A and 2B). Again,
increasing the antigen dose above 0.5 mg did not signif-
icantly increase the neutralization titer. This suggests
that antigen doses as low as 0.5 mg were still saturating
when administered in the presence of Freund’s adjuvant.
FIG. 1. Analysis of HPV-33 VLPs and capsomeres by electron mi-
croscopy, SDS–PAGE, and neutralization assays. (A) Electron micro-
graphs of HPV-33 VLPs and capsomeres purified from Sf9 insect cells
infected with recombinant baculoviruses carrying HPV-33 wild-type L1
(wt) or the HPV-33 L1 mutant 33L1-C427S (C427S). Photographs were
taken with a Zeiss EM900 transmission electron microscope at an
instrumental magnification of 330,000 (VLPs) and 350,000 (capso-
meres), respectively. (B) SDS–PAGE of VLPs and capsomeres. Both
proteins were detected after Western blotting with mAb 33L1-7 using
enhanced chemiluminescence. The apparent molecular weights of
marker proteins are indicated in kilodaltons. (C) Neutralization assays
of antisera raised against HPV-33 VLPs and capsomeres, respectively.
Pseudovirions of HPV-33, encapsidating pSVbgal, were incubated with
indicated dilutions of VLP and capsomere antiserum, respectively, and
were subsequently used to infect COS-7 cells. The average of three
independent experiments is shown.We then repeated the dose–response analysis in the
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355CAPSOMERES OF HPV-33 INDUCE NEUTRALIZING ANTIBODIESabsence of adjuvant (Table 1). As expected, the immune
response directed against both VLPs and capsomeres
was greatly reduced. The highest endpoint titer obtained
with capsomeres as antigen was 2.9 3 105 compared to
3 107 obtained in the presence of adjuvant. The differ-
ence was even more pronounced for VLPs. Analysis of
these antisera in neutralization assays revealed a signif-
icant difference between capsomeres and VLPs.
Whereas 1.5 mg VLPs was sufficient to induce a measur-
ble virus-neutralizing immune response, 14 mg capso-
eres was needed (Figs. 2C and 2D). Our data suggest
hat VLPs have a 10- to 20-fold higher capacity than
apsomeres to induce neutralizing antibodies but that
TABLE 1
ELISA Endpoint Titers of VLP and Capsomere Antisera
Antigen dose
VLP sera Capsomere sera
CFA PBS CFA PBS
0.5 mg 2.7 3 106 n.d. 2.8 3 106 n.d.
1.5 mg 2.7 3 106 2.5 3 104 3.9 3 106 5.3 3 104
4.5 mg 4.2 3 106 1.4 3 104 3.4 3 106 1.9 3 105
7.0 mg 3.8 3 106 n.d. 1.0 3 107 n.d.
14 mg 8.2 3 106 4.3 3 104 1.0 3 107 2.9 3 105
Note. CFA, immunization carried out in Freund’s adjuvant; PBS, im-
munization carried out in PBS; n.d., not done.
FIG. 2. Neutralization assays. HPV-33 pseudovirions were incubated
obtained by immunization of three mice each with the amounts of an
neutralization assays with antisera obtained by immunization with VLP
adjuvant, respectively, are shown. An infectivity of 100% corresponds to
of at least three independent neutralization assays.his difference can be overcome by increasing the anti-
en dose.
We have recently shown that the neutralizing antibod-
es induced by VLPs are, with few exceptions, type-
pecific and no cross-neutralization between HPV-16,
18, and -33 was observed (Giroglou et al., 2001b). Since
e reasoned that disassembly of VLPs into capsomeres
ight possibly unmask cross-reactive epitopes, we
ested the HPV-33 VLP and capsomere antisera for
ross-reactivity by ELISA using HPV-16 and -18 VLPs as
ntigen and for neutralization of HPV-16 and -18
seudovirions. We chose the antisera with the highest
PV-33 neutralization titers for this analysis in order to
etect even a low level of cross-reactivity and cross-
eutralization. For all types tested we observed that the
apsomere antiserum had an eightfold higher cross-
eactivity in ELISA than the VLP antiserum, but neither
he VLP nor the capsomere antiserum cross-neutralized
PV-16 and -18, not even at low dilution (Table 2). This
uggests that the majority of epitopes inducing cross-
eactive antibodies are masked inside the VLP structure
nd become accessible in capsomeres.
Clinical studies using virus-like particles as vaccine
ave been initiated to fight papillomavirus-induced dis-
ases. In animal studies, systemic immunization with
LPs prevented infection with mucosal papillomaviruses
n a type-specific manner, and serum immunoglobulins
assively transferred to naive animals conferred protec-
h at 37°C at the indicated dilutions with pooled antisera, which were
iven, and were then evaluated in an infectivity assay. The results of
) and capsomeres (B, D) in the presence (A, B) and absence (C, D) of
rage of 60 infected cells. Each bar corresponds to the average valuesfor 1
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356 FLIGGE ET AL.tion from experimental infection (Breitburd et al., 1995;
Suzich et al., 1995). A drawback to a wide application of
VLPs as vaccine may be the difficulty of producing suf-
ficient amounts at reasonable cost using eukaryotic ex-
pression systems. We have shown in this paper that a
subunit of HPV-33 VLPs, the pentameric capsomere, car-
ries sufficient structural information to induce neutraliz-
ing antibodies even at low doses. Production of capso-
meres in a prokaryotic host should be less costly than
production of VLPs in eukaryotic cells. Rose et al. (1998)
reviously reported that the neutralization potential of
LPs and capsomeres of HPV-11 produced in Esche-
richia coli were comparable, when tested in rabbits in
he presence of Freund’s adjuvant. We have now shown
hat capsomeres elicit type-specific neutralizing antibod-
es even in the absence of adjuvant. Although the neu-
ralization titers found were lower than those obtained
ith VLPs, this disadvantage may be overcome by the
se of an adjuvant appropriate for human vaccination.
ur data and those of Rose et al. taken together suggest
that capsomeres may substitute VLPs as future vaccine.
Experiments using an animal model have now to be
carried out to verify that systemic immunization with
capsomeres confers immunity to viral challenge.
MATERIALS AND METHODS
Preparation of HPV-33 VLPs and capsomeres
VLPs and capsomeres were obtained using the bac-
ulovirus system. After extraction from nuclei of insect
cells infected with recombinant baculovirus bac33L1,
VLPs were partially purified by two successive cesium
chloride buoyant density-gradient centrifugations as de-
scribed previously (Volpers et al., 1994). Capsomeres
were obtained from insect cells infected with bac33L1-
C427S encoding a mutant L1 protein with serine replac-
ing cysteine-427 (Sapp et al., 1998) and were purified by
cesium chloride centrifugation. Both VLPs and capso-
meres were recovered from the gradients at a density of
1.29 g/cm3. The amount of L1 protein in VLPs and cap-
omeres was determined by sodium dodecyl sulfate–
olyacrylamide gel electrophoresis (SDS–PAGE) and
estern blotting using monoclonal antibody 33L1-7
TABLE 2
Cross-Neutralization Analysis
Titer
HPV-33 VLP
antiserum
HPV-33 capsomere
antiserum
Antibody titer 8.2 3 106 1.0 3 107
Neutralization titer
HPV-16 ,10 ,10
HPV-18 ,10 ,10
HPV-33 .4500 .4500Sapp et al., 1994). An affinity-purified glutathioneS-transferase fusion protein (G33L1-293/313) served as
standard for the quantitative estimate (Sapp et al., 1995).
Preparation of pseudovirions
Pseudovirions of HPV-33, HPV-16, and HPV-18 encap-
sidating the marker plasmid pSVbgal or pEGFP-GFP-
LS, respectively, were produced in COS-7 cells with
ome modifications of the described procedure (Unckell
t al., 1997). The plasmid pEGFP-GFP-NLS codes for a
imer of the green fluorescent protein to which the nu-
lear localization signal (NLS) of HPV-33 L1 was fused in
rame. COS-7 cells were electroporated with one of the
arker plasmids and grown for 48 h followed by infection
ith recombinant vaccinia viruses carrying the L1 and L2
enes of HPV-33, HPV-16, and HPV-18, respectively, and
he helper virus VTF7-3. After cultivation for an additional
0 h, cells were collected, resuspended in hypotonic
uffer, and disrupted in a dounce homogenizer. Nuclei
ere sedimented, resuspended in PBS containing 0.5%
onidet P-40, and subjected to mild sonication. Nonidet
-40 was added in order to destroy contaminating vac-
inia virus, which might interfere with our assay. The
leared lysate was layered on top of a sucrose step
radient (2 ml 70% and 3 ml 30% sucrose in PBS, pH 6.8).
fter centrifugation for 4 h at 40,000 rpm (SW40 rotor),
ractions were collected from the bottom and analyzed by
estern blotting and infectivity assays as described pre-
iously (Unckell et al., 1997).
Electron microscopy
VLPs and capsomeres were dialyzed against PBS and
spotted onto carbon-coated copper grids. VLPs were
negatively stained with 5% ammonium molybdate (pH
7.0) supplemented with 1% trehalose; capsomeres were
stained with 2% phosphotungstic acid (pH 7.0). Photo-
graphs were taken with a Zeiss EM900 transmission
electron microscope at an instrumental magnification of
330,000 (VLPs) and 350,000 (capsomeres), respectively.
Immunization of mice
VLPs and capsomere preparations were extensively
dialyzed against PBS. Two hundred fifty microliters of 1:1
emulsions of VLPs and capsomeres in complete
Freund’s adjuvant, respectively, were used for intraperi-
toneal immunization of three Balb/c mice each. Mice
were boostered twice with the same antigen dose sus-
pended in incomplete Freund’s adjuvant after 3 and 6
weeks. Two weeks after each boost, blood was collected
and analyzed by ELISA and neutralization assays. For
immunization without adjuvant VLPs and capsomeres
were diluted in a total volume of 250 ml PBS.
nzyme-linked immunosorbent assay
Purified VLPs were diluted in PBS to 1 mg/ml, and
100-ml aliquots were dispensed into wells of 96-well
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357CAPSOMERES OF HPV-33 INDUCE NEUTRALIZING ANTIBODIESmicrotiter plates. After incubation at 4°C overnight,
plates were washed and saturated with PBS supple-
mented with 0.1% Tween-20 and 0.5% bovine serum al-
bumin. Twofold serial dilutions of antisera were tested in
duplicate. For each antiserum the endpoint titer was
calculated.
Neutralization assays
Assays were performed with slight modifications of
the published protocol (Unckell et al., 1997). Pseudoviri-
ons were preincubated with antiserum dilutions for 1 h at
37°C with 100 mg/ml DNAse I in a total volume of 30 ml
BS, pH 6.8, 10 mM MgCl2. Subsequently 6.6 3 10
4
COS-7 cells suspended in 300 ml PBS, pH 6.8, supple-
ented with 100 mg/ml bovine serum albumin were
dded. After incubation for 1 h at 4°C under constant
gitation, cells were seeded into 24-well plates and
rown for 72 h. For detection of cells infected with
seudovirions containing pSVbGal, the monolayers were
fixed and stained as described previously (Unckell et al.,
1997). For detection of cells expressing GFP, medium
was removed from the monolayers and green cells were
counted under a fluorescence microscope.
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